Any current/future new fundraising through debt or equity?

There is no mention of any current or planned fundraising through debt or equity in the transcript. The company discusses capacity expansions and new product commercialization mostly funded through existing resources and potential capex internally decided. For some scalable products (e.g., agro intermediates), additional rounds of capex might be considered later, but no specific fundraising plan is shared. Focus remains on organic growth, capacity utilization, and new product development without reference to external fundraising activities.

Any current/future capex/capital investment/strategic investment?

A new plant is being designed at Jolva, with groundbreaking planned for January-February 2026 to accommodate a large scalable agrochemical product. This new facility will help overcome production bottlenecks for newly commercialized agro and pharma intermediates. Additional capex rounds may be considered for scaling up certain agro products as demand grows. Plant scale changes are underway to enable delivery of commercial batches for semiconductor chemicals, targeted for Q4 of the current financial year. Ongoing investment in R&D for advanced products in semiconductor and electrolyte salt spac

Future growth expectations in sales/revenue/volumes?

**SDA Segment**: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters. **Agro Products**: Anticipated 1.5x volume growth next financial year and another 1.5x growth in the following year. New agro intermediate with significant domestic demand expected to become a key product by 2027. **Electrolyte Salts**: Revenue projected to reach around INR15 crore in the current year, scaling up to 10% of total revenue by FY'27 with consistent volume growth and regular dispa

Future growth expectations in earnings/operating earnings/profits/EPS?

Strong growth expected in SDA segment with volumes set to increase significantly from 2026 due to new customer onboarding and Euro 7 norms-driven demand. EBITDA margins in SDA anticipated to improve to 20-22% as plant occupancy reaches full capacity in next 2 quarters. Electrolyte Salt segment projected to grow steadily, reaching around INR15 crores revenue in current year and rising to ~10% of total revenue by FY '27. Pharma and agro intermediates expected to scale with INR300-350 crores potential revenue at full capacity in 2-3 years. Semiconductor chemicals segment targeting commercializati

Current/ Expected Orderbook/ Pending Orders?

The company is currently executing trial orders for individual solar plant energy shields in the energy storage system segment, indicating the beginning of commercialization. Small-scale commercial orders have been executed for hybrid batteries used in automotive applications, with positive customer feedback. Goods in transit for the PASC (Phase Transfer Catalysts) segment have increased from INR16-17 crores last quarter to INR26 crores this quarter, reflecting an active order pipeline. New large-scale agro intermediate commercialization has commenced, with production activities progressing as

IN US

Sale is live|00:00:00left today

Tatva Chintan Pharma Chem LtdQ3 FY25Chemicals & Petrochemicals

Tatva Chintan Pharma Chem Ltd Q3 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,194P/E: 73.2Market Cap: ₹3.1K CrSector: Chemicals & Petrochemicals

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

Yes

Capex

Yes

2 of 4 growth signals are positive.

Full analysis

Revenue guidance

Category 2

→**SDA Segment**: Strong volume uptick expected from 2026 onward as new customers onboard; pricing bottomed out with expected increase, leading to improved EBITDA margins to 20-22% within two quarters.
→**Agro Products**: Anticipated 1.5x volume growth next financial year and another 1.5x growth in the following year. New agro intermediate with significant domestic demand expected to become a key product by 2027.
→**Electrolyte Salts**: Revenue projected to reach around INR15 crore in the current year, scaling up to 10% of total revenue by FY'27 with consistent volume growth and regular dispatches.
→**Pharma and Agro Intermediates**: Four agro and four pharma molecules expected to reach full potential in 2-3 years, collectively addressing a revenue potential of INR300-350 crore.
→**Semiconductor Chemicals**: Gradual commercialization expected starting end of 2027 or early 2028, with meaningful business in 2-3 years.
→**Overall**: Continued volume growth supported by new plant commissioning in January 2026, enhancing capacity and cost efficiency.

Margin guidance

Category 3

→Strong growth expected in SDA segment with volumes set to increase significantly from 2026 due to new customer onboarding and Euro 7 norms-driven demand.
→EBITDA margins in SDA anticipated to improve to 20-22% as plant occupancy reaches full capacity in next 2 quarters.
→Electrolyte Salt segment projected to grow steadily, reaching around INR15 crores revenue in current year and rising to ~10% of total revenue by FY '27.
→Pharma and agro intermediates expected to scale with INR300-350 crores potential revenue at full capacity in 2-3 years.
→Semiconductor chemicals segment targeting commercialization from late 2027 / early 2028, with margins comparable or better than SDA.
→Current low ROCE (~4% pre-tax) to improve with rising plant utilization; EBITDA from new plant could reach INR175 crores.
→Overall, firm outlook on revenue and earnings growth driven by capacity utilization, product innovation, and new commercializations over medium term.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no mention of any current or planned fundraising through debt or equity in the transcript.
→The company discusses capacity expansions and new product commercialization mostly funded through existing resources and potential capex internally decided.
→For some scalable products (e.g., agro intermediates), additional rounds of capex might be considered later, but no specific fundraising plan is shared.
→Focus remains on organic growth, capacity utilization, and new product development without reference to external fundraising activities.

Order book

Yes

→The company is currently executing trial orders for individual solar plant energy shields in the energy storage system segment, indicating the beginning of commercialization.
→Small-scale commercial orders have been executed for hybrid batteries used in automotive applications, with positive customer feedback.
→Goods in transit for the PASC (Phase Transfer Catalysts) segment have increased from INR16-17 crores last quarter to INR26 crores this quarter, reflecting an active order pipeline.
→New large-scale agro intermediate commercialization has commenced, with production activities progressing as planned.
→Validation batches for new pharma and agro intermediates are underway, with commercialization expected from December 2025 to the second half of 2026.
→The semiconductor product pipeline includes products in piloting, with expected revenues ranging INR50-100 crores.
→New customers onboarding in SDA (Structure Directing Agents) expected to drive meaningful business starting 2026.
→Current electrolyte salt business has transitioned from inconsistent to regular supply, with consistent orders and expected revenue growth starting Q3 FY26.

Capex plans

Yes

→A new plant is being designed at Jolva, with groundbreaking planned for January-February 2026 to accommodate a large scalable agrochemical product.
→This new facility will help overcome production bottlenecks for newly commercialized agro and pharma intermediates.
→Additional capex rounds may be considered for scaling up certain agro products as demand grows.
→Plant scale changes are underway to enable delivery of commercial batches for semiconductor chemicals, targeted for Q4 of the current financial year.
→Ongoing investment in R&D for advanced products in semiconductor and electrolyte salt spaces.
→The new plant block is expected to be available for commercial production starting January 2026 to improve operational efficiency and capacity utilization.

How does Tatva Chintan Pharma Chem Ltd rank vs peers in Chemicals & Petrochemicals?

Pro feature

1Tatva Chintan Pharma Chem Ltd

Rev 2Mar 3

See full Chemicals & Petrochemicals sector rankings

Want more stocks like Tatva Chintan Pharma Chem Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio